<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658671</url>
  </required_header>
  <id_info>
    <org_study_id>2076-CL-001</org_study_id>
    <nct_id>NCT00658671</nct_id>
  </id_info>
  <brief_title>A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer</brief_title>
  <official_title>An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose-escalation trial designed to assess the safety and tolerability of treatment with&#xD;
      ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is&#xD;
      refractory to current treatment or for which no curative therapy exists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ENMD-2076</measure>
    <time_frame>Throughout study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PK</measure>
    <time_frame>Throughout study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of benefit (tumor response, clinical benefit, or tumor marker improvement, if appropriate)</measure>
    <time_frame>Throughout study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced cancer, excluding patients with colorectal or ovarian cancers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent or resistant epithelial ovarian cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENMD-2076</intervention_name>
    <description>Capsules, daily dosing in 28 day cycles</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologic proof of advanced cancer that has progressed after treatment and has&#xD;
             no standard therapy that is curative or provides clinical benefit.&#xD;
&#xD;
          -  Meet the modified RECIST Criteria or have disease that can be followed for clinical&#xD;
             benefit.&#xD;
&#xD;
          -  Are greater than or equal to 18 years of age.&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1500 cells/mm3&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Agree to use effective contraceptive methods prior to study entry, during study&#xD;
             participation, and for at least 30 days after the last administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Have the ability to understand the requirements of the study, provide written informed&#xD;
             consent which includes authorization for release of protected health information,&#xD;
             abide by the study restrictions, and agree to return for the required assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or nursing.&#xD;
&#xD;
          -  Have received radiotherapy or chemotherapy less than two weeks prior to first dose of&#xD;
             study medication and have not recovered from all acute toxicities from prior&#xD;
             treatments.&#xD;
&#xD;
          -  Have participated in any clinical trial involving conventional or investigational&#xD;
             drugs within 28 days prior to initiation of ENMD-2076 dosing.&#xD;
&#xD;
          -  Have active, acute, or chronic clinically significant infections.&#xD;
&#xD;
          -  Have uncontrolled severe hypertension or congestive heart failure.&#xD;
&#xD;
          -  Have active angina pectoris or recent myocardial infarction (within 6 months).&#xD;
&#xD;
          -  Have chronic atrial fibrillation or QTc of greater than 470 msec.&#xD;
&#xD;
          -  Have had major surgery within 21 days of starting therapy.&#xD;
&#xD;
          -  Have planned surgical treatment of tumor(s)&#xD;
&#xD;
          -  Have additional uncontrolled serious medical or psychiatric illness.&#xD;
&#xD;
          -  Have any medical condition that would impair the administration of oral agents&#xD;
             including significant bowel resection, inflammatory bowel disease or uncontrolled&#xD;
             nausea or vomiting.&#xD;
&#xD;
          -  Have a 2+ protein by urinalysis or a history of nephrotic syndrome.&#xD;
&#xD;
          -  Known central nervous system metastasis.&#xD;
&#xD;
          -  Have history of deep vein thrombosis or pulmonary embolus, unless they are receiving&#xD;
             therapeutic anticoagulation with warfarin or low-molecular-weight heparin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Gannon, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>CASI Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber/Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2011 Feb 15;17(4):849-60. doi: 10.1158/1078-0432.CCR-10-2144. Epub 2010 Dec 3.</citation>
    <PMID>21131552</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 11, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

